Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK2 | P49760 | 13/20 | 0.51 |
| ▸ | CLK3 | P49761 | 12/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 12/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | WNT1 | P04628 | 4/20 | 0.47 |
| ▸ | TTK | P33981 | 1/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2399375 | 0.94 | TTK (0.50) | CLK2CLK3DYRK1AMAPK10WNT1 | |
| SCHEMBL2396969 | 0.89 | CHEK1 (0.42) | CLK2CLK3DYRK1AMAPK10TTK | |
| SCHEMBL1558650 | 0.87 | MTOR (0.49) | CLK2CLK3DYRK1AWNT1TTK | |
| SCHEMBL2396580 | 0.85 | MAPK10 (0.44) | CLK2CLK3DYRK1AMAPK10 | |
| SCHEMBL1557469 | 0.79 | CLK2 (0.51) | CLK2CLK3DYRK1AWNT1 | |
| SCHEMBL1557578 | 0.79 | RAF1 (0.51) | CLK2CLK3DYRK1AMAPK10NTRK1 | |
| SCHEMBL2395780 | 0.77 | DYRK1A (0.48) | CLK2CLK3DYRK1AWNT1 | |
| SCHEMBL2396806 | 0.77 | CLK2 (0.50) | CLK2CLK3DYRK1AWNT1 | |
| SCHEMBL2396769 | 0.77 | MTOR (0.42) | CLK2CLK3DYRK1AWNT1 | |
| SCHEMBL1559106 | 0.77 | MTOR (0.50) | DYRK1ATTKMAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212053-A1 | PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS | PROGENICS PHARMACEUTICALS, INC. | 2011-09-01 | — | — | US | disclosed |
| US-20110212053-A1 | PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS | PROGENICS PHARMACEUTICALS, INC. | 2011-09-01 | — | — | US | disclosed |
| WO-2009155527-A9 | PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS | PROGENICS PHARMACEUTICALS, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
| WO-2009155527-A2 | PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS | PROGENICS PHARMACEUTICALS, INC. (US) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212053-A1 | PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS | PIK3CA, AKT1, PIK3R5 | CLK2 408/4885CLK3 506/4885DYRK1A 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.